Invesaro

Stocks RCUS Earnings

Earnings

Arcus Biosciences, Inc. (RCUS) earnings

Quarterly results of Arcus Biosciences, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when RCUS files with the SEC.

Next earnings date

Arcus Biosciences, Inc. is expected to report around February 24, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q3 FY2026

In Q3 FY2026 (ended September 30, 2026) Arcus Biosciences, Inc. reported revenue of $9M (-65.4% on the same quarter a year earlier) and a net loss of $128M.

Diluted earnings per share were -$1.00.

Filed with the SEC on November 4, 2026.

Revenue by quarter
Q4 24: $26M $26M Q4 24Q1 25: $28M $28M Q1 25Q2 25: $160M $160M Q2 25Q3 25: $26M $26M Q3 25Q4 25: $33M $33M Q4 25Q1 26: $17M $17M Q1 26Q2 26: $41M $41M Q2 26Q3 26: $9M $9M Q3 26
Net income by quarter
Q4 24: -$94M -$94M Q4 24Q1 25: -$112M -$112M Q1 25Q2 25: $0 $0 Q2 25Q3 25: -$135M -$135M Q3 25Q4 25: -$106M -$106M Q4 25Q1 26: -$128M -$128M Q1 26Q2 26: -$91M -$91M Q2 26Q3 26: -$128M -$128M Q3 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q3 FY2026September 30, 2026$9M-65.4%-$128M-$1.00
Q2 FY2026June 30, 2026$41M-74.4%-$91M-$0.72
Q1 FY2026March 31, 2026$17M-39.3%-$128M-$1.02
Q4 FY2025December 31, 2025$33M+26.9%-$106M-
Q3 FY2025September 30, 2025$26M--$135M-$1.27
Q2 FY2025June 30, 2025$160M-$0$0.00
Q1 FY2025March 31, 2025$28M--$112M-$1.14
Q4 FY2024December 31, 2024$26M--$94M-

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Arcus Biosciences, Inc.'s next earnings date?

Arcus Biosciences, Inc. is expected to report around February 24, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

What were Arcus Biosciences, Inc.'s latest quarterly results?

For Q3 FY2026, which ended September 30, 2026, Arcus Biosciences, Inc. reported revenue of $9M and a net loss of $128M. The figures come from its filing with the SEC.

Is Arcus Biosciences, Inc.'s revenue growing?

Revenue in Q3 FY2026 was $9M, down 65.4% from $26M in the same quarter a year earlier.

Get an email when RCUS reports

Follow RCUS and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when RCUS files with the SEC.

Source: quarterly figures Arcus Biosciences, Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Arcus Biosciences, Inc.